Giota Touloumi

Prof. Giota Touloumi

Medical School, National and Kapodistrian University of Athens, Athens, Greece
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2012 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
GTGiota Touloumi
Giota Touloumi
NPNikos Pantazis
Nikos Pantazis
DPDeenan Pillay
Deenan Pillay
Dimitrios ParaskevisDimitrios Paraskevis
Dimitrios Paraskevis
MCMarie-Laure Chaix
Marie-Laure Chaix
CECASCADE collaboration in EuroCoord
CASCADE collaboration in EuroCoord
Background. Human immunodeficiency virus type 1 (HIV-1) subtype may influence disease progression. We compared CD4 lymphocyte cell count levels at seroconversion, decline rates and viral load set point in individuals infected with different HIV-1 subtypes. Methods. We used data from the Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE) collaboration, restricted to those infected since 1996, aged ≥15 years, and applied mixed effects models for CD4 cell count decline and median regression for viral load set point (mean level 6–24 months from seroconversion). Results. The analysis included 3364 seroconverters with known HIV-1 subtypes. Compared with subtype B, CD4 at seroconversion was significantly higher for subtype CRF01 and lower for subtype C. Subsequent CD4 decline was significantly slower for subtypes A and CRF02 and marginally slower for subtype C compared with B. Mean CD4 loss at 2 years of seroconversion for white men exposed through sex between men, aged 30–39 years, having seroconverted since 2006, enrolled within 6 months of seroconversion, and without acute infection was 88, 142, 100, 130, 103, and 167 cells/µL for subtypes A, B, C, CRF01_AE, CRF02_AG, and G, respectively. In adjusted analysis, median viral load set point and time to clinical AIDS/death did not differ significantly by subtype, although all subtypes, except C, tended to have lower levels compared with B. Conclusions. HIV-1 subtype significantly influences seroconversion CD4 cell levels and decline rates but not viral load set point. These findings may be helpful to HIV-positive individuals and their attending physicians in understanding disease progression.

15 June 2022 in Journal of Psychosomatic Research
Verified
Journal Article
Closed access
ACAnna Christodoulaki
Anna Christodoulaki
VBValia Baralou
Valia Baralou
ΓΚΓεώργιος Κωνσταντακόπουλος
Γεώργιος Κωνσταντακόπουλος
GTGiota Touloumi
Giota Touloumi

21 September 2006 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
GTGiota Touloumi
Giota Touloumi
ESE. Samoli
E. Samoli
MPM. Pipikou
M. Pipikou
ATA. Le Tertre
A. Le Tertre
RAR. Atkinson
R. Atkinson
KKK. Katsouyanni
K. Katsouyanni

30 March 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GTGiota Touloumi
Giota Touloumi
NKNatasa Kalpourtzi
Natasa Kalpourtzi
VPVasileios Papastamopoulos
Vasileios Papastamopoulos
VPVasilios Paparizos
Vasilios Paparizos
GAGeorgios Adamis
Georgios Adamis
OEOn Behalf Of The Amacs And Emeno
On Behalf Of The Amacs And Emeno
Although combined antiretroviral therapy has substantially improved the prognosis of people living with HIV (PLHIV), mortality remains higher compared to the general population, mainly due to higher prevalence of non-HIV-related comorbidities, including cardiovascular diseases (CVD). We assessed the prevalence of CVD risk and its contributing factors in adult PLHIV versus general population controls in Greece. Cross-sectional comparison of PLHIV (Athens-Multicenter-AIDS-Cohort-Study; AMACS) versus general population controls (National health examination survey; EMENO). All HIV-infected adults with ≥1 measurement of interest (blood pressure, lipids, glucose, weight, height) between 2012–2014 and all EMENO participants (2014–2016) were included. Ten-year total CVD risk was estimated using the Framingham (FRS) or the Systematic Coronary Risk Evaluation (SCORE) equations. 5839 PLHIV (median age:41.6 years, 85.4% males) and 4820 controls (median age:48 years, 48.4% males) were included. Adjusting for age, sex and origin, PLHIV were more likely to be current smokers (adjusted OR:1.53 [95% CI:1.35–1.74]) and dyslipidemic (aOR:1.18; [1.04–1.34]), less likely to be obese (aOR:0.44 [0.38–0.52], with no differences in hypertension, diabetes or high (≥20%) FRS but with greater odds of high (≥5%) SCORE (aOR:1.55 [1.05–2.30]). Further adjustment for educational level, anti-HCV positivity and BMI showed higher prevalence of hypertension in PLHIV. Despite the relative absence of obesity, PLHIV have higher prevalence of traditional CVD risk factors and higher risk of fatal CVD compared to general population. Regular screening and early management of CVD risk factors in PLHIV should be of high priority for CVD prevention.

7 November 2020 in BMC Public Health
Verified
Journal Article
Open access
PDF file
OGon behalf of the EMENO study group
on behalf of the EMENO study group
GTGiota Touloumi
Giota Touloumi
AKArgiro Karakosta
Argiro Karakosta
NKNatasa Kalpourtzi
Natasa Kalpourtzi
MGMagda Gavana
Magda Gavana
GSGeorge Stergiou
George Stergiou
Background: Nationwide data on cardiovascular risk factors prevalence is lacking in Greece. This work presents the findings of the national health examination survey EMENO (2013–2016) regarding the prevalence of hypertension, hypercholesterolemia, diabetes, obesity and smoking. Methods: A random sample of adults (≥18 years) was drawn by multistage stratified random sampling based on 2011 Census. All EMENO participants with ≥1 measurement of interest [blood pressure (BP), fasting glucose, HbA1c, total cholesterol (TC), Body Mass Index (BMI)] were included. Hypertension was defined as BP ≥ 140/90 mmHg and/or antihypertensive treatment; diabetes as fasting glucose≥126 mg/dL and/or HbA1c ≥ 6.5% or self-reported diabetes; hypercholesterolemia as TC ≥ 190 mg/dL. Sampling weights were applied to adjust for study design and post-stratification weights to match sample age and sex distribution to population one. Non-response was adjusted by inverse probability weighting. Results: Of 6006 EMENO participants, 4822 were included (51.5% females, median age:47.9 years). The prevalence of hypertension was 39.2%, higher in men (42.4%) than in women (36.1%); of hypercholesterolemia 60.2%, similar in men (59.5%) and women (60.9%); of diabetes 11.6%, similar men (12.4%) and women (10.9%); of obesity 32.1%, higher in women (33.5% vs 30.2%), although in subjects aged 18–40 year it was higher in men; of current smoking 38.2%, higher in men (44.0%) than in women (32.7%). The prevalence of all risk factors increased substantially with age, except smoking, which followed an inverse U shape. Conclusions: The burden of cardiovascular risk factors among Greek adults is alarming. There is considerable preventive potential and actions at health care and societal level are urgently needed.

1 January 2005 in Epidemiology
Verified
Journal Article
Closed access
GTGiota Touloumi
Giota Touloumi
ESEvangelia Samoli
Evangelia Samoli
PQPhilippe Quénel
Philippe Quénel
APAnna Paldy
Anna Paldy
RARoss H. Anderson
Ross H. Anderson
KKKlea Katsouyanni
Klea Katsouyanni
Air pollution is associated with total mortality. This association may be confounded by uncontrolled time-varying risk factors such as influenza epidemics. We analyzed independent data on influenza epidemics from 7 European cities that also had data on mortality associated with particulates (PM10). We used 10 methods to control for epidemics (5 derived from influenza data and 5 from respiratory mortality series) and compared those results with analyses that did not control for these epidemics. Adjustment for influenza epidemics increased the PM10 effect estimate in most cases (% change in the pooled regression coefficient: −1.9 to 38.9 for total mortality and 1.3 to 25.5 for cardiovascular mortality). A 10-μg/m3 increase in PM10 concentrations (lag 0–1) was associated with a 0.48% (95% confidence interval = 0.27–0.70%) increase in daily mortality unadjusted for influenza epidemics, whereas under the various methods to control for epidemics the increase ranged from 0.45% (0.26–0.69%) to 0.67% (0.46–0.89%). The corresponding figures for cardiovascular mortality were 0.85% (0.53–1.18%) with no adjustment and from 0.86% (0.53–1.19%) to 1.06% (0.74–1.39%) with the methods of control. The association between air pollution and mortality is not weakened by control for influenza epidemic irrespective of the method used. To adjust for influenza epidemics, one can use methods based on respiratory mortality counts instead of counts of influenza cases if the latter are not available. However, adjustment for influenza by any method tested did not markedly alter the air pollution effect estimate.